###### Strengths and limitations of this study

-   This is the first study to analyse the safety and efficacy of cystine and theanine in patients with colorectal cancer treated with capecitabine after surgery.

-   This is an adequately powered study to provide a clinically meaningful outcome.

-   This study is an exploratory trial; a confirmatory trial with a larger sample size will be required subsequently.

Introduction {#s1}
============

In recent years, the number of deaths from colorectal cancer in Japan has been increasing remarkably. According to vital statistics in Japan, 2016,[@R1] in women colorectal cancer is the leading cause of death above all other cancers. In men, the number of colorectal cancer deaths follows that of lung cancer and stomach cancer and the difference in the number of deaths occurring between stomach cancer and colorectal cancer has been shrinking gradually in the past several years.

In the early stages of colorectal cancer, surgical operation, including endoscopic surgical removal, is recommended, and in locally advanced cancers, combined chemotherapy after surgery is usually performed. For patients with rectal cancer, a combination of radiotherapy with chemotherapy before surgery may be a treatment option. In advanced or recurrent cancers, chemotherapy is the main treatment and surgery is performed only when it is possible. In addition, for clinical stage III disease, adjuvant chemotherapy may be considered. In Japan, uracil-tegafur (UFT)/leucovorin (LV) is the standard adjuvant oral chemotherapy based on the National Surgical Adjuvant Breast and Bowel Project C-06 trial.[@R2] On the other hand, in Europe and USA, 5-fluorouracil (5-FU)/LV plus oxaliplatin is the standard therapy; however, this is not the case in Japan owing to the high frequency of adverse events (AEs) associated with 5-FU/LV plus oxaliplatin, such as haematotoxicity and peripheral neuropathy, as well as the good surgical results in Japan. S-1 and capecitabine are also oral pyrimidine fluoride anticancer drugs. Recently, it was reported that adjuvant chemotherapy using S-1 for stage III colon cancer was confirmed to be non-inferior in disease-free survival rates compared with UFT/LV.[@R3] On the other hand, a randomised phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colon cancer (JCOG0910) failed to demonstrate the non-inferiority of adjuvant S-1 compared with capecitabine treatment regarding disease-free survival.[@R4] Furthermore, the non-inferiority of adjuvant capecitabine compared with 5-FU/LV treatment regarding disease-free survival was reported in a randomised phase III trial.[@R5] Therefore, among the oral pyrimidine fluoride anticancer drugs, adjuvant capecitabine remains the standard treatment for stage III colon cancer.

Capecitabine, however, often causes hand-foot syndrome (HFS) as an AE,[@R6] as well as gastrointestinal symptoms, such as stomatitis, anorexia, diarrhoea, bone marrow suppression and an increase in hepatobiliary enzyme levels.[@R7] These AEs not only negatively affect treatment course but also affect a patient's quality of life (QOL). There are no standard prevention therapies for these AEs and withdrawal or a reduced dosage of capecitabine with symptomatic treatment is often required when they occur. Therefore, reduction or prevention therapy for AEs that may improve the completion rate of capecitabine treatment is considered to be useful.

Cystine and theanine {#s1a}
--------------------

Cystine and theanine are amino acids that are known to be precursors involved in the synthesis of glutathione (GSH) in humans. GSH is vital for antioxidation reactions that reduce reactive oxygen species, such as peroxides and free radicals, and is a substrate in conjugation reactions for detoxification. Glutamine is a precursor of GSH and similarly to cystine/theanine is reported to be effective for preventing and treating oral mucositis in patients receiving mucotoxic cancer chemotherapy.[@R8] In addition, it was reported that GSH has neuroprotective effects on oxaliplatin-based chemotherapy.[@R9] Perioperative oral administration of cystine/theanine was also reported to suppress inflammation and enhance recovery after surgery.[@R10]

Previous research has shown that oral administration of cystine/theanine attenuates the AEs of S-1 adjuvant chemotherapy in patients with colorectal cancer after surgery.[@R11] The incidence rate of diarrhoea was significantly less in the cystine/theanine group (4.5%) than in the control group (41.7%). The completion rate of the first course of S-1 adjuvant chemotherapy at the prescribed dose was significantly higher in the cystine/theanine group (90.9%) than in the control group (41.7%). These results of previous studies suggest that cystine/theanine will attenuate the AEs and improve the QOL of patients treated with capecitabine which is an oral pyrimidine fluoride anticancer drug similar to S-1. Therefore, we will analyse the efficacy of cystine/theanine in a randomised, double-blinded, placebo-controlled study.

Methods and analysis {#s2}
====================

Design {#s2a}
------

This study is a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial aimed to investigate the safety and efficacy of oral administration of cystine/theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery ([figure 1](#F1){ref-type="fig"}). The protocol of this study followed the Standard Protocol Items for Randomized Trials statement and its checklist (online [supplementary appendix 1](#SP2){ref-type="supplementary-material"}).[@R12]
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![Flow chart of the study. Participants will be randomised (1:1 allocation ratio) into the cystine/theanine group (n=50) or the placebo group (n=50).](bmjopen-2017-021442f01){#F1}

Study setting {#s2b}
-------------

This study is multi-institutional with four participating institutions located in Japan, as follows: Sendai Open Hospital, Iwate Prefectural Central Hospital, Yamagata Prefectural Central Hospital and Tohoku Rosai Hospital.

Patient and public involvement {#s2c}
------------------------------

Patients and/or public were not involved.

Randomisation, blinding, safety assessment and data collection {#s2d}
--------------------------------------------------------------

### Randomisation {#s2d1}

Eligible patients will be enrolled in the Japanese Organisation for Research and Treatment of Cancer (JORTC) data centre using a web-based electronic data capturing system. Patients will be randomly assigned to either the cystine/theanine group or the placebo group, using stratified permuted block randomisation methods and a computer-generated randomisation schedule with a 1:1 allocation ratio, balanced for the following stratification factors: (1) study site, (2) age (\<71 or≥71 years) and (3) site of cancer (colon or rectum).

### Blinding {#s2d2}

Patients and investigators responsible for treatment will be blinded to the administered reagent (cystine/theanine or placebo). The study drugs will be packaged in a way in which they cannot be distinguished from one another.

### Safety assessment {#s2d3}

AEs will be graded according to the Common Terminology Criteria for AEs (CTCAE) v.4.0, Japanese Clinical Oncology Group (JCOG) version. HFS will be assessed by the HFS grading scale suggested by Blum *et al* ([table 1](#T1){ref-type="table"}).[@R13]

###### 

Hand-foot syndrome grading scale\* (modified from[@R13])

  Grade   Clinical domain†                                                              Functional domain
  ------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------
  1       Numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema.   Discomfort that does not disrupt normal activities.
  2       Painful erythema with swelling.                                               Discomfort that affects activities of daily living.
  3       Moist desquamation, ulceration, blistering and severe pain.                   Severe discomfort, unable to work or perform activities of daily living.

\*This scale applies only for the grading of hand-foot syndrome and not for any other skin abnormalities and/or other cutaneous areas.

†In the case of a discrepancy between clinical and functional domains, the assigned grade will be the higher of the grades.

### Health-related QOL assessment {#s2d4}

Health-related QOL will be assessed using the following patient-reported outcome measures: the Japanese version of the European Organisation for Research and Treatment of Cancer (EORTC) QOL questionnaire module for all patients with cancer (QLQ-C30) and for patients with colorectal cancer (QLQ-CR29).

### Data collection {#s2d5}

We will collect basic data, such as sex, age, histology of colorectal cancer, cancer stage, daily living ability using the Eastern Cooperative Oncology Group scale of performance status (PS), height, weight and current treatment, at enrolment. Within 3 days before each capecitabine treatment course, we will analyse the weight, PS, AEs according to CTCAE v.4.0-JCOG, such as haematology (leucocytes, neutrophil counts, haemoglobin and platelets), serum chemistry (total bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP) and creatinine), HFS grading scale ([table 1](#T1){ref-type="table"}),[@R13] QOL questionnaire (EORTC QLQ-C30 and QLQ-CR29 scores), adherence to cystine/theanine or placebo and combination treatments, until completion of protocol treatment. The data after completion (four courses) will be investigated within 3 days before the start of the fifth course of treatment. When capecitabine treatment is discontinued in the middle of a treatment course, we will collect the data within 3 days after termination of treatment.

### Eligibility criteria {#s2d6}

Eligible patients satisfying the inclusion criteria will be recruited. Inclusion and exclusion criteria are listed in [box 1](#BX2){ref-type="boxed-text"}.Box 1Inclusion and exclusion criteriaInclusion criteriaUnderstanding of the nature and consequences of the study and voluntary signature of the informed consent document.Age ≥20 and ≤80 years at the time of consent.Histologically confirmed colorectal cancer after surgery.Agree to undergo adjuvant chemotherapy after surgery and plan to receive capecitabine therapy.Eastern Cooperative Oncology Group Performance Status ≤1.Laboratory findings within the following ranges (at ≤14 days prior to enrolment); leucocytes ≥3.0x10^9^/L, platelets ≥75x10^9^/L, haemoglobin ≥9.0 g/dL, total bilirubin ≤2.0 mg/dL, aspartate aminotransferase ≤100 U/L, alanine aminotransferase ≤100 U/L, serum creatinine ≤1.5 mg/dL.Exclusion criteriaPrevious treatment with chemotherapy.Previous treatment with radiation.Currently taking dietary supplements containing amino acids or protein (allowed if discontinued for more than 7 days before the start of the study).Previous administration of cystine or theanine.Currently taking dietary supplements derived from herbs (such as St John's wort or others) except for multivitamins.Pregnant or breast feeding.Immune deficiency.Phenylketonuria.Enrolment in other clinical trials.Cognitive disorder prior to enrolment.Psychiatric disorder that may affect data sampling.Unable to communicate verbally.Incapable of oral ingestion.Malabsorption syndrome.History of gastrectomy.Active gastrointestinal bleeding unrelated with cancer.Investigator considers that the patient is not suitable for the study.

Estimated timeline {#s2e}
------------------

Recruitment of study patients was initiated on 14 November 2016 and is expected to be completed by 30 April 2018. The trial is expected to be finished by 30 September 2018.

Treatment {#s2f}
---------

In this study, patients with colorectal cancer who are scheduled to receive capecitabine therapy as an adjuvant chemotherapy after surgery will be administered cystine/theanine or placebo as an intervention therapy. Capecitabine therapy will be conducted in accordance with prescribing information[@R7]: 1250 mg/m^2^ twice daily orally (morning and evening; equivalent to 2500 mg/m^2^ total daily dose) for 2 weeks followed by a 1-week rest period in 3-week cycles for a total of eight courses (24 weeks). The dose is calculated according to body surface area (BSA) ([table 2](#T2){ref-type="table"}). AEs caused by capecitabine administration may be managed by dose interruptions and adjustment of capecitabine dose ([table 3](#T3){ref-type="table"}). The dose reduction calculations according to BSA are shown in [table 4](#T4){ref-type="table"}.

###### 

Capecitabine dose calculation according to body surface area

  Dose level: 1250 mg/m^2^ twice a day   
  -------------------------------------- -------------------
  \<1.33                                 3000 (10 tablets)
  1.33--1.56                             3600 (12 tablets)
  1.57--1.80                             4200 (14 tablets)
  ≥1.81                                  4800 (16 tablets)

###### 

Recommended dose modifications of capecitabine

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Toxicity\        During the course of therapy                                                                                  Dose adjustment for next treatment (% of starting dose)
  CTCAE grades\*                                                                                                                 
  ---------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  Grade 1          Maintain dose level                                                                                           Maintain dose level

  Grade 2                                                                                                                        

  1st appearance   Interrupt until resolved to grade 0--1                                                                        100%

  2nd appearance   75%                                                                                                           

  3rd appearance   50%                                                                                                           

  4th appearance   Discontinue treatment permanently                                                                             --

  Grade 3                                                                                                                        

  1st appearance   Interrupt until resolved to grade 0--1                                                                        75%

  2nd appearance   50%                                                                                                           

  3rd appearance   Discontinue treatment permanently                                                                             --

  Grade 4                                                                                                                        

  1st appearance   Discontinue treatment permanently or\                                                                         --\
                   If physician decides continuation is in the patient's best interest, interrupt until resolved to grade 0--1   50%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Common Terminology Criteria for Adverse Events v.4.0, Japanese Clinical Oncology Group version.

###### 

Capecitabine dose reduction calculation according to body surface area

  Surface area (m^2^)   Total daily dose (mg)                      
  --------------------- ----------------------- ------------------ ------------------
  \<1.13                3000 (10 tablets)       1800 (6 tablets)   1200 (4 tablets)
  1.13--1.20            2400 (8 tablets)                           
  1.21--1.32            1800 (6 tablets)                           
  1.33--1.44            3600 (12 tablets)                          
  1.45--1.56            3000 (10 tablets)                          
  1.57--1.68            4200 (14 tablets)                          
  1.69--1.76            2400 (8 tablets)                           
  1.77--1.80            3600 (12 tablets)                          
  ≥1.81                 4800 (16 tablets)                          

Interventions {#s2g}
-------------

Cystine/theanine or placebo will be administered in one dose every morning from the start of capecitabine therapy. The intervention period will be four courses of capecitabine therapy ([figure 2](#F2){ref-type="fig"}). Cystine/theanine or placebo administration will be continued for the entire 5-week course of capecitabine therapy, unless there is an interruption owing to AEs. Cystine/theanine or placebo administration will be ended in accordance with the discontinuation criteria. To improve the adherence to intervention treatment, we will collect adherence records from participants at the beginning of each course (except for the first course).

![Schematic diagram of capecitabine and intervention treatment.](bmjopen-2017-021442f02){#F2}

### Cystine/theanine {#s2g1}

L-cystine (700 mg), L-theanine (270 mg) and other ingredients (maltitol, aspartame and citric acid) to a total of 1.5 g.

### Placebo {#s2g2}

Palatinose (833 mg), powdery starch syrup (147 mg) and other ingredients (maltitol, aspartame and citric acid) to a total of 1.5 g.

The amount of aspartame administered to the placebo group was 0.45 mg less in each dose than the treatment group, to balance for the sweetness of Palatinose and powdery starch syrup.

Discontinuation criteria {#s2h}
------------------------

Protocol treatment (cystine/theanine or placebo) will be discontinued in the following cases: (1) patient wishes to discontinue study participation, (2) recurrence of colorectal cancer, (3) complicated by another cancer, (4) CTCAE grade 3 or higher for cystine/theanine or placebo, (5) the investigator judges that it is difficult for the patient to continue the protocol treatment owing to AEs, (6) CTCAE grade 4 for capecitabine, (7) discontinuation of capecitabine treatment for longer than 3 weeks, (8) unable to continue capecitabine treatment owing to AEs, (9) patient wishes to discontinue capecitabine treatment, (10) death during protocol treatment, (11) unable to continue protocol treatment owing to a change in hospital, (12) acute progression of disease or the revelation of ineligibility or protocol violations after enrolment and (13) the investigator decides to discontinue protocol treatment due to various medical reasons.

The investigators will judge whether or not the AEs are a result of cystine/theanine or placebo. Capecitabine treatment will be continued as standard clinical therapy after discontinuation of protocol treatment based on the investigators' judgement. Dose reduction or interruption of capecitabine therapy will be considered when AEs of grade 2 or higher occur ([table 3](#T3){ref-type="table"}). Dose modifications of capecitabine treatment will be in accordance with the prescribing information ([table 4](#T4){ref-type="table"}) and will finally depend on the investigators' decision.

Supportive treatment {#s2i}
--------------------

Dietary supplements or other drugs that contain amino acids and proteins will be prohibited because they may affect the results of the study. The concomitant use of other drugs with capecitabine will be in accordance with the prescribing information[@R7] and the site investigators' decision. Use of other drugs and treatment concomitantly with intervention treatment will be permitted in accordance with the judgement of the site investigators. The concomitant use of drugs or treatment will be recorded regarding duration and reasons for use.

### Supportive treatment for HFS {#s2i1}

Little is known about the development of HFS and no standard prevention for HFS has been established. However, non-pharmacological interventions are recommended for the relief of symptoms, such as avoidance of pressure, prevention of injury and elevation or cooling of the hands and feet.[@R14] Topical steroids or moisturising agents are commonly used as pharmacological interventions. Oral pyridoxine was reported to relieve symptoms of HFS, but meta-analysis failed to show any preventive effects.[@R15] In addition, the COX-2 inhibitor celecoxib was reported to reduce the overall incidence of HFS.[@R17]

In clinical settings, moisturisation is considered to be important as a prophylactic treatment for HFS. Appropriate use of a moisturising cream may help to reduce the incidence of HFS. A randomised comparative study on prophylaxis for capecitabine-associated HFS demonstrated that a urea cream was superior to a medical ointment containing antioxidants and nourishing oil extracts (Mapisal, Medac, Wedel, Germany).[@R19]

In this trial, moisturising therapy with urea cream as a supportive treatment for HFS will be conducted from the start of protocol treatment. If the patients are taking other drugs or treatments for HFS, their durations and reasons for use will be recorded.

Urea ointment: Urepearl, Keratinamin, Pastaron and so on.

Directions for use: apply to hands and feet, three times a day, each time after washing hands.

Study endpoints {#s2j}
---------------

### Primary endpoint {#s2j1}

Primary endpoint is incidence rate of diarrhoea of grade 1 or higher (CTCAE v.4.0-JCOG).

### Secondary endpoints {#s2j2}

Secondary endpoints are EORTC QLQ-C30 and EORTC QLQ-CR29 scores; incidence rate of HFS of grade 1 or higher (HFS grading scale); incidence rate of diarrhoea of grade 2 or higher (CTCAE v.4.0-JCOG); incidence rates of AEs according to CTCAE v.4.0-JCOG of grade 1 or higher, grade 2 or higher (haematology (leucocytes, neutrophil counts, haemoglobin and platelets), serum chemistry (total bilirubin, ALP, AST, ALT, γ-GTP and creatinine), and other AEs according to CTCAE v.4.0-JCOG); adherence to protocol; completion rate of four courses of capecitabine, and the proportion of completion without delay or dose reduction; time to completion (four courses of capecitabine) and total dose of capecitabine.

Statistical analysis {#s2k}
--------------------

### Study populations for analyses {#s2k1}

Efficacy and safety will be analysed using all randomised patients who have received at least one administration of protocol treatment. Analysis of efficacy will exclude all ineligible patients detected after randomisation, although they will be included in the analysis of safety.

### Analysis plan {#s2k2}

The primary endpoint of incidence rate of diarrhoea of grade 1 or higher (CTCAE v.4.0-JCOG) will be analysed using a one-sided Fisher's exact test at a significance level of 5%. Point estimates and 90% CIs for the difference between two groups will be calculated.

### Sample size calculation {#s2k3}

A previous study showed that cystine/theanine reduced the rate of diarrhoea of S-1 adjuvant chemotherapy in patients with colorectal cancer after surgery. The incidence rate of diarrhoea was significantly less in the cystine/theanine group (4.5%) than in the control group (41.7%).[@R11] Cystine/theanine therapy is expected to attenuate the diarrhoea of patients treated with capecitabine which is an oral pyrimidine fluoride anticancer drug similar to S-1. The incidence rate of diarrhoea after capecitabine monotherapy according to the prescribing information is 36.8%.[@R7] Based on these data, we estimated that the incidence rate of diarrhoea after capecitabine monotherapy will be 5% with cystine/theanine and 25% with placebo. Therefore, assuming a rate of exclusion of 10%, 50 samples are required for each group (100 samples in total) to achieve a statistical power of 80% with a one-sided significance level of 5%. Incidence rates of AEs will be analysed using the Fisher's exact test (one-sided).

Ethical aspects, informed consent and safety {#s2l}
--------------------------------------------

All study procedures are in accordance with the Declaration of Helsinki and the Japanese ethical guidelines for clinical research. Written informed consent from each patient will be obtained prior to enrolment (online [supplementary appendix 2](#SP1){ref-type="supplementary-material"}). An independent data monitoring committee will oversee the trial and will verify the trial procedure based on ongoing evaluation and safety data. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000024784 on 10 November 2016. Modifications in the study protocol will be communicated to the institutional review board (IRB) at each participating institution as well as the independent data monitoring committee. Each ethics committee or IRB will review the informed consent materials given to the participants and adapt them in accordance with their own institutional guidelines.
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Discussion {#s3}
==========

Capecitabine therapy as an adjuvant chemotherapy for patients with colorectal cancer after surgery is expected to extend disease-free survival. However, capecitabine often causes AEs that affect the continuation of treatment and patients' QOL. Therefore, reduction or prevention therapy for AEs that may improve the completion rate of capecitabine treatment is required. To the best of our knowledge, there are no randomised studies on the efficacy of cystine/theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery. In this study, we conduct a multi-institutional, randomised, double-blinded, placebo controlled, phase II trial which is the most appropriate design to demonstrate the efficacy of a new therapy.

Cystine and theanine are amino acids contained in various foods and they are permitted as food additives and hence widely used. No severe AEs caused by cystine/theanine have been reported in research on humans.[@R20] A previous study reported that cystine/theanine attenuated the AEs of S-1 adjuvant chemotherapy in patients with colorectal cancer after surgery.[@R11] Cystine/theanine are expected to attenuate AEs and improve the QOL of patients treated with capecitabine which is an oral pyrimidine fluoride anticancer drug, similar to S-1.

Cystine/theanine will become a possible option for reduction or prevention therapy for AEs that may occur due to capecitabine therapy in patients with colorectal cancer after surgery, and in addition, we will plan to conduct a phase III trial, if this study demonstrates the attenuation of AEs and improves the QOL of patients treated with capecitabine.

Trial status {#s3a}
------------

Enrolment started in November 2016. At the time of manuscript submission (December 2017) 52 patients have already been enrolled. We expect to finish patient recruitment by April 2018.

Confidentiality {#s3b}
---------------

Data will be retained in accordance with the Japanese ethical guidelines for clinical research. Participants will be allocated a unique identification (ID) number at enrolment. The master list linking personal information of the participants and ID number will be maintained in a separate locked cabinet and a password-protected hard drive at each institution. Data will be analysed by ID number only. Records will be retained for 5 years after study completion and then will be destroyed by the data centre.

Ethics and dissemination {#s3c}
------------------------

The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at conferences. Participants will be informed of the results of the trial by the investigators. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidelines.
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